Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition
-
- Hitendra S. Solanki
- 1Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Eric A. Welsh
- 2Biostatistics and Bioinformatics Shared Resources, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Bin Fang
- 3Proteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Victoria Izumi
- 3Proteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Lancia Darville
- 3Proteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Brandon Stone
- 3Proteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Ryan Franzese
- 3Proteomics & Metabolomics Core, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Sandip Chavan
- 4Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Fumi Kinose
- 1Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Denis Imbody
- 1Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- John M. Koomen
- 4Molecular Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Uwe Rix
- 6Department of Drug Discovery, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
-
- Eric B. Haura
- 1Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Description
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose:</jats:title> <jats:p>Covalent inhibitors of KRASG12C specifically target tumors driven by this form of mutant KRAS, yet early studies show that bypass signaling drives adaptive resistance. Although several combination strategies have been shown to improve efficacy of KRASG12C inhibitors (KRASi), underlying mechanisms and predictive strategies for patient enrichment are less clear.</jats:p> </jats:sec> <jats:sec> <jats:title>Experimental Design:</jats:title> <jats:p>We performed mass spectrometry–based phosphoproteomics analysis in KRASG12C cell lines after short-term treatment with ARS-1620. To understand signaling diversity and cell type–specific markers, we compared proteome and phosphoproteomes of KRASG12C cells. Gene expression patterns of KRASG12C cell lines and lung tumor tissues were examined.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Our analysis suggests cell type–specific perturbation to ERBB2/3 signaling compensates for repressed ERK and AKT signaling following ARS-1620 treatment in epithelial cell type, and this subtype was also more responsive to coinhibition of SHP2 and SOS1. Conversely, both high basal and feedback activation of FGFR or AXL signaling were identified in mesenchymal cells. Inhibition of FGFR signaling suppressed feedback activation of ERK and mTOR, while AXL inhibition suppressed PI3K pathway. In both cell lines and human lung cancer tissues with KRASG12C, we observed high basal ERBB2/3 associated with epithelial gene signatures, while higher basal FGFR1 and AXL were observed in cells/tumors with mesenchymal gene signatures.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>Our phosphoproteomic study identified cell type–adaptive responses to KRASi. Markers and targets associated with ERBB2/3 signaling in epithelial subtype and with FGFR1/AXL signaling in mesenchymal subtype should be considered in patient enrichment schemes with KRASi.</jats:p> </jats:sec>
Journal
-
- Clinical Cancer Research
-
Clinical Cancer Research 27 (9), 2533-2548, 2021-02-22
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1360294647798043136
-
- ISSN
- 15573265
- 10780432
-
- Data Source
-
- Crossref